title: Clostridium difficile Associated Diarrhea.
abstract: Clostridium difficile associated diarrhea (CDAD) is increasingly important in primary care, and associated with high cost, significant morbidity and mortality. As the preferred treatment for different groups of patients varies considerably, it is important to stratify CDAD patients into mild versus severe and uncomplicated versus complicated. While treatment with either metronidazole or oral vancomycin cures a majority of patients, and despite improvement in early diagnosis and therapy, recurrence continues to be a significant problem. In appropriately selected patients, fecal bacteriotherapy has emerged as an effective treatment for the patient with multiple recurrences. Addressing CDAD should include antibiotic stewardship, improved hygiene, prompt diagnosis, appropriate treatment, and infection precautions in hospitals and skilled nursing facilities.
authors.forename: Noah
authors.initials: N
authors.lastname: Wiedel
authors.forename: Jorge
authors.initials: J
authors.lastname: Gilbert
authors.forename: Brett
authors.initials: B
authors.lastname: Baloun
authors.forename: Chelsea
authors.initials: C
authors.lastname: Nelson
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016360:Clostridioides difficile / Q000502:physiology; D003967:Diarrhea / Q000175:diagnosis* / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D004761:Enterocolitis, Pseudomembranous / Q000175:diagnosis* / Q000382:microbiology / Q000517:prevention & control / Q000628:therapy*; D000069467:Fecal Microbiota Transplantation; D006801:Humans; D008795:Metronidazole / Q000627:therapeutic use; D012008:Recurrence; D014640:Vancomycin / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D008795:Metronidazole; D014640:Vancomycin